

## Randomized, Double-blind Pilot Study of Nanocurcumin in Bladder Cancer Patients Receiving Induction Chemotherapy

Saleh Sandoughdaran<sup>1</sup>, Abolfazl Razzaghdoost<sup>2,\*\*</sup>, Ali Tabibi<sup>3</sup>, Abbas Basiri<sup>3</sup>, Nasser Simforoosh<sup>3</sup>,  
Bahram Mofid<sup>1,\*</sup>

**Purpose:** To evaluate the feasibility and potential efficacy of nanocurcumin supplementation in patients with localized muscle-invasive bladder cancer (MIBC) undergoing induction chemotherapy.

**Materials and Methods:** In this double-blind, placebo-controlled trial, 26 MIBC patients were randomized to receive either nanocurcumin (180 mg/day) or placebo during the course of chemotherapy. All patients were followed up to four weeks after the end of treatment to assess the complete clinical response to the chemotherapy as primary endpoint. Secondary endpoints were the comparisons of chemotherapy-induced nephrotoxicity, hematologic nadirs, and toxicities between the two groups. Hematologic nadirs and toxicities were assessed during the treatment.

**Results:** Nanocurcumin was well tolerated. The complete clinical response rates were 30.8 and 50% in the placebo and nanocurcumin groups, respectively. Although nanocurcumin was shown to be superior to placebo with respect to complete clinical response rates as the primary endpoint, there was no significant difference between the groups ( $p = 0.417$ ). No significant difference was also found between the two groups with regard to grade 3/4 renal and hematologic toxicities as well as hematologic nadirs.

**Conclusion:** These preliminary data indicate the feasibility of nanocurcumin supplementation as a complementary therapy in MIBC patients and support further larger studies. Moreover, a substantial translational insight to fill the gap between the experiment and clinical practice in the field is provided.

**Keywords:** curcumin; induction chemotherapies; neoplasm; urinary bladder

### INTRODUCTION

Bladder cancer is one of the most common forms of cancer in men and women worldwide<sup>(1)</sup>. Despite several efforts to improve the treatment outcome of patients with muscle-invasive bladder cancer, the complete response rate of neoadjuvant chemotherapy remains to be around 30% over the last decade<sup>(2)</sup>. Therefore, an effective complementary therapy to the chemotherapy is needed to achieve better outcomes. In some in vitro and in vivo studies, substantial chemosensitization by curcumin has been shown in the bladder tumor cells as well as many other cancers<sup>(3-15)</sup>. The emergence of such preclinical evidence for synergistic effect of curcumin with other chemotherapeutic drugs makes it a potential complementary therapy to be used in clinical practice<sup>(16)</sup>. At the cellular level, synergistic anticancer effect of SinaCurcumin® in combination with cisplatin has also been shown<sup>(15)</sup>. In spite of several promising roles for the curcumin in preclinical models, clinical evidence is equivocal due to inappropriate clinical pharmacokinetics such as low oral bioavailability and rapid metabolism<sup>(17)</sup>. Novel drug delivery systems have recently been designed to

improve pharmacokinetics of anticancer phytochemicals including curcumin<sup>(18)</sup>. Curcumin nanoformulations have shown substantial potential to overcome the problem<sup>(19)</sup>. In a recent study, Yu et al. have reviewed the recent progress of the drug delivery systems aiming at bladder cancer therapy<sup>(20)</sup>. Recently, various clinical trials have focused on the use of SinaCurcumin®, a novel nanoformulation of curcuminoids, in different settings and disorders<sup>(21-24)</sup>. The results of these clinical studies are encouraging and suggest further research. Although some larger studies have investigated the complementary role of nanocurcumin in diverse range of cancer patients, but its value in the setting of bladder cancer patients undergoing induction chemotherapy has not yet been assessed. Therefore, we conducted this pilot randomized trial to investigate the feasibility and clinical efficacy of nanocurcumin in this setting. In the light of this pilot study, further larger definitive trials could clarify the clinical utility of nanocurcumin as a complementary therapy in these patients.

<sup>1</sup>Department of Radiation Oncology, Shohada-e-Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>2</sup>Urology and Nephrology Research Center, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>3</sup>Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


\*Correspondence: Shohada-e-Tajrish Medical Center, Shahr-dari St, Tajrish Sq., Tehran, Iran.

Postal Code: 1989934148, Tel/Fax: +98 21 22739200, Email: mofid429@sbmu.ac.ir.

\*\*Urology and Nephrology Research Center, No.103, Boostan 9th St., Pasdaran Ave., Tehran, Iran.

Postal code: 1666663111, Tel: +98 21 22567222, Fax: +98 21 22567282, Email: razzaghdoost@sbmu.ac.ir

Received November 2019 & Accepted April 2020



**Figure 1.** The CONSORT flow chart of patients

## MATERIAL AND METHODS

### Study design

This stratified, randomized, double-blind, placebo-controlled pilot study was conducted at two tertiary hospitals in Tehran, Iran, from September 2016 to February 2018. Consecutive male and female patients with histologically confirmed muscle-invasive bladder cancer (clinical stage T2-T4a) who had undergone initial transurethral resection of bladder tumor (TURBT) were assessed for eligibility. All patients were candidates for platinum-based neoadjuvant chemotherapy and have the performance status of 0 or 1. All participants had to have adequate baseline bone marrow and hepatic function. Patients with metastatic disease (N+, M+) were excluded from the study. The protocol of this study was in accordance with the Helsinki declaration and approved by the ethics committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.MSP.REC.1396.227). All patients provided signed informed consent before inclusion in the study. This trial was registered on [www.irct.ir](http://www.irct.ir) (Identifier: IRCT20180226038875N1). Since Julious (2005) recommended a sample size of 12 per group as a rule of thumb in pilot studies, we planned to enroll a total of 24 participants in two groups<sup>(25)</sup>. Eligible patients were randomly assigned to one of two parallel groups in a 1:1 ratio to receive chemotherapy with either oral capsule nanocurcumin (SinaCurcumin®) or placebo using an internet-generated randomization list prepared by an investigator with no clinical involvement in the trial. The participants were stratified by the chemotherapy regimens (gemcitabine/cisplatin vs. gemcitabine/carboplatin) and treatment centers. The nanocurcumin capsules were prepacked in sequentially

numbered containers according to the randomization list. The randomization list was concealed from patients and all clinical investigators. An off-site person has labeled the drug packages with coded numbers. Each block of eight numbers was transmitted from the central office to an independent individual (a person not involved in the patient recruitment and treatment) in each center. Each participant was assigned an order number and received the capsules in the corresponding numbered containers.

### Treatment schedule

All participants were randomized to receive chemotherapy with either oral capsule nanocurcumin 80 mg (SinaCurcumin®) or placebo two times daily. SinaCurcumin®, a commercially available capsule containing curcuminoids as nanomicelles, was prepared by the Exir Nano Sina Company, Tehran, Iran. Placebo capsules were provided by the same company as nanocurcumin and were perfectly matched in size, shape, odor, and color. The mean diameter of nanomicelles is around 10 nm, according to dynamic light scattering. Pharmacokinetic features of SinaCurcumin® have been recently published<sup>(26)</sup>. The authors declared that the bioavailability of SinaCurcumin® as a nanomicelle was estimated to be 59.2 times higher than its free form. All patients were administered gemcitabine (1000 mg/m<sup>2</sup>, intravenous (IV), 30 min) on days 1 and 8, every 21 days. Following gemcitabine administration, patients with a creatinine clearance >60 ml/min received cisplatin on days 1 and 2 every 21 days (70 mg/m<sup>2</sup>, 60 min) whereas those with a creatinine clearance <60 ml/min received carboplatin (AUC = 5, IV over 30 min) on day 1 every 21 days. Carboplatin doses were adjusted for renal function as per label using the Cockcroft-Gault formula.

### Outcomes and assessment

The primary endpoint was complete clinical response to the chemotherapy as assessed four weeks after the end of treatment, using cystoscopy procedure performed by an independent blinded urologist. Eligible patients who received the treatment and had the follow-up tumor assessment were assessable for response. A clinical complete response to the induction chemotherapy defined as no evidence of primary tumor (T0) on cystoscopic assessment with biopsy. Complete blood count (CBC) test, hemoglobin, platelets, creatinine level, serum urea, liver enzymes, Creactive protein, and erythrocyte sedimentation rate were evaluated at baseline, prior to each chemotherapy cycle, and after the treatment course. Secondary endpoints were the comparisons of chemotherapy-induced nephrotoxicity, hematologic toxicities, and nadirs between the two groups. The lowest level of the hematologic parameters obtained after start of the chemotherapy course was selected as the nadir value. All toxicities were graded using the National Cancer Institute (NCI) common terminology criteria for adverse event (CTCAE) version 4.03.

### Statistical analyses

Pearson's chi-square and Fisher's exact tests were used to compare the complete response rate as well as toxicities between the nanocurcumin and placebo groups. The baseline-adjusted hematologic nadirs were compared by analysis of covariance (ANCOVA) test. Mann-Whitney *U* test and Fisher's exact test were used for between-group comparison of the baseline charac-

**Table 1.** Baseline characteristics of patients

Characteristics	Placebo (n = 14)	Nanocurcumin (n = 12)	P-value
Age, mean (SE), years	64.7 (2.4)	68.2 (3.7)	0.462 <sup>a</sup>
Height, mean (SE),cm	166.5 (2.9)	169.5 (1.9)	0.595 <sup>a</sup>
Weight, mean (SE), kg	77.0 (4.9)	74.3 (2.7)	0.999 <sup>a</sup>
Regimen, n (%)			
Gem/Cis	8 (57.1)	8 (66.7)	0.701 <sup>b</sup>
Gem/Carbo	6 (42.9)	4 (33.3)	
Creatinine clearance, mean (SE), mL/min	59.3 (7.3)	62.6 (5.8)	0.432 <sup>a</sup>
Hemoglobin, mean (SE), g/dl	13.0 (0.5)	13.5 (0.4)	0.899 <sup>a</sup>
Platelets, mean (SE), 109/L	277 (20)	240 (15)	0.131 <sup>a</sup>
Leucocytes, mean (SE), 109/L	7.9 (0.7)	8.2 (0.6)	0.467 <sup>a</sup>

SE, Standard Error of mean; Gem, Gemcitabine; Cis, Cisplatin; Carbo, Carboplatin

<sup>a</sup> Mann-Whitney U test was used

<sup>b</sup> Fisher's exact test was used

teristics. Missing data were handled by the complete case analysis. The statistical analyses were performed using the IBM SPSS Statistics for Windows, Version 23.0 (IBM Corp., Armonk, N.Y., USA). All statistical tests were performed at the two-tailed 5% level of significance.

## RESULTS

### Patient characteristics

From September 2016 to February 2018, a total of 36 patients were assessed for eligibility. Of these, 26 patients were included in the study and randomized to receive placebo or nanocurcumin (Figure 1). Patient demographics are summarized in Table 1. Nanocurcumin was well tolerated. One patient in the nanocurcumin group had a cardiac arrest from previously unrecognized 3-vessel coronary artery disease. Cisplatin-related pulmonary infection, renal failure, and skin rash were also reported in three patients receiving nanocurcumin.

### Tumor response

Using a per-protocol approach, 13 patients in the placebo group and 10 patients in the nanocurcumin group were analyzed for treatment response. Tumor downstaging to pT0 was achieved in 39.1% of all patients. The complete clinical response rate was 30.8% (4/13) in the placebo group and 50% (5/10) in the nanocurcumin group. Although nanocurcumin was shown to be superior to placebo with respect to the primary endpoint, there

was no significant difference between the groups ( $p = 0.417$ ). There was no significant difference between the patients receiving cisplatin and carboplatin regarding the complete clinical response rate ( $p = 0.999$ ).

### Hematologic nadirs and toxicity

Secondary outcomes were analyzed on an intention-to-treat basis and all patients receiving treatment ( $n = 26$ ) were included in the toxicity assessment. The baseline-adjusted hematologic nadirs in the placebo and nanocurcumin groups are indicated in Table 2. No significant differences were found in the nadir levels between the two groups. Grade 3/4 toxicities are indicated in Table 3. As shown in the Table, no significant differences were observed between the two groups in terms of grade 3/4 renal and hematologic toxicities.

## DISCUSSION

Chemotherapeutic agents e.g. cisplatin could induce inflammatory responses and this inflammation may reduce the treatment efficacy<sup>(27)</sup>. Hence, targeting of inflammation via combined use of anti-inflammatory agents and conventional cancer therapy is a rational approach<sup>(28,29)</sup>. Several studies have shown that curcumin could inhibit pro-inflammatory and inflammatory factors e.g. nuclear factor-kappa B (NF-κB), and consequently result in chemosensitization in the cancer cells as well as chemoprotection in the normal cells (12,30-33). Furthermore, a series of target molecules e.g. apop-

**Table 2.** Hematologic nadirs with adjustment for baseline values

parameter	Nadir value a, mean (SE)		Between-group difference, mean (95% CI)	P-value <sup>b</sup>
	Placebo	Nanocurcumin		
Leucocytes	3.3 (0.1)	3.0 (0.2)	0.3 (-0.2 to 0.9)	0.203
Neutrophils	1.2 (0.2)	1.0 (0.2)	0.2 (-0.2 to 0.8)	0.323
Lymphocytes	1.7 (0.2)	1.3 (0.2)	0.4 (-0.2 to 0.9)	0.177
Hemoglobin	9.5 (0.4)	10.2 (0.4)	0.7 (-0.7 to 0.1.9)	0.354
Platelets	170 (7)	167 (7)	3 (-18 to 26)	0.732
Creatinine clearance	56.4 (3.8)	47.7 (4.1)	8.7 (-3.1 to 20.5)	0.142

<sup>a</sup> Units of the parameters: creatinine clearance (mL/min); leucocytes, neutrophils, lymphocytes, and platelets (109/L); hemoglobin level (g/dL)

<sup>b</sup> ANCOVA test was used for all parameters with adjustment for baseline values of each parameter

**Table 3.** Chemotherapy-induced toxicities (Grade 3/4)

Endpoint	Placebo group (n = 14)	Nanocurcumin group (n = 12)	P-value
Leukopenia, n (%)	2 (14.3)	1 (8.3)	0.999 <sup>a</sup>
Neutropenia, n (%)	5 (35.7)	7 (58.4)	0.249 <sup>b</sup>
Anemia, n (%)	1 (7.1)	1 (8.3)	0.999 <sup>a</sup>
Thrombocytopenia, n (%)	0	0	-
Nephrotoxicity, n (%)	1 (7.1)	2 (16.7)	0.580 <sup>a</sup>

<sup>a</sup> Fisher's exact tests was used<sup>b</sup> Pearson's chi-square test was used

tosis-related proteins, adhesion molecules, transcription factors, growth factors, and some key enzymes such as cyclooxygenase-2 (COX-2), lipoxygenase (LOX), and inducible nitric oxide synthase (iNOS) may be involved in this dual function<sup>(30,31,34)</sup>.

The direct antitumor activity of curcumin in bladder cancer cells has also been shown in several previous studies *in vitro* and *in vivo*<sup>(35,36)</sup>. The post-transcriptional activity of curcumin via down-regulation of miR-7641 and subsequent up-regulation of p16 has been reported in bladder cancer cells<sup>(37)</sup>. Wang et al. (2018) concluded that this regulation could lead to the decreased invasion and increased apoptosis of the bladder cancer cells. The administration of curcumin, as a chemopreventive agent, following the BCG therapy of bladder cancer has also been suggested by Hauser et al. (2007)<sup>(36)</sup>.

Several promising preclinical studies have reported the complementary role of curcumin in combination with chemotherapy in different types of cancer<sup>(3-7)</sup>. Du et al. (2006) indicated a synergism between curcumin and 5-fluorouracil in HT-29 cell line, associated with a 6-fold reduction in the expression of COX-2 protein<sup>(3)</sup>. Dhandapani et al. (2007) showed that curcumin could suppress the cancer cell growth and chemoresistance of several chemotherapeutic agents such as cisplatin<sup>(4)</sup>. Also, the reduced chemoresistance of both cisplatin-resistant and wild-type cancer cells was also reported by Montopoli et al. (2009)<sup>(5)</sup>. In the mentioned study and another *in vitro* study on MCF-7 and MDA-MB-231 cells<sup>(6)</sup>, the cell cycle inhibition and apoptosis induction were observed. Furthermore, Zhang et al. (2018) demonstrated that curcumin in combination with cisplatin could significantly decrease proliferation and increase the apoptosis of A549 cells<sup>(8)</sup>. The authors also indicated that curcumin may hinder copper influx and increase uptake of platinum ion in cancer cells. They concluded that the process of chemosensitization to cisplatin therapy is regulated by the Cu-Sp1-CTR1 regulatory loop. In a former study, the direct antitumor activity of curcumin as a copper chelator is also described by Zhang et al. (2016)<sup>(38)</sup>.

In preclinical models, the complementary role of curcumin in combination with antineoplastic agents has been well documented in bladder cancer cells<sup>(9-12)</sup>. In an *in vitro* study, Amanollahi et al. (2018) reported the synergistic effect of Curcumin and mitomycin in bladder cancer cells<sup>(9)</sup>. In their study, curcumin significantly decreased cell viability with increasing curcumin concentrations. They also declared that beside the antineoplastic activity in cancer cells, curcumin could protect normal cells from adverse effects of mitomycin. Although the potential chemoprotective role of curcumin against chemotherapy-induced myelosuppression and

nephrotoxicity has been previously discussed in the literature<sup>(30,32,33)</sup>, no protective effect was established in this study. Moreover, Afsharmoghadam et al. (2017) indicated a concentration-dependent effect of curcumin on antineoplastic activity of 5-fluorouracil in bladder cancer cells<sup>(10)</sup>. Their results suggest a critical role for curcumin concentration in the degree of cytotoxicity induced by chemotherapeutic agents. In another study, Park et al. (2016) explored the synergistic effect of curcumin combined with cisplatin to induce apoptosis in 253J-Bv (p53 wild-type) and T24 (p53 mutant) bladder cancer<sup>(11)</sup>. In both p53 wild-type and mutant bladder cancer cells treated with combination therapy, the apoptosis rate was increased compared to that in cells exposed to monotherapy. This synergistic interaction was found to be associated with the activation of reactive oxygen species (ROS) and extracellular regulated kinase (ERK) signaling. The authors hypothesized that curcumin and cisplatin combination therapy can be an effective and reliable approach for the management of human bladder cancer. Beside the cisplatin, a significant synergistic inhibitory effect of curcumin in combination with gemcitabine and carboplatin, as two other agents used in this study, was also reported<sup>(12,13)</sup>. For instance, the combined apoptotic effect of curcumin and gemcitabine in bladder cancer cells was investigated by Kamat et al. (2007)<sup>(12)</sup>. They interestingly found that curcumin suppressed the gemcitabine-induced NF-κB activation in the bladder cancer cells.

While mentioned studies have addressed the complementary role of curcumin as a chemosensitizer in pre-clinical models, several gaps between the experiment and clinical practice remain to be filled. Recent studies have indicated that the poor clinical pharmacokinetics of curcumin could be improved using novel drug delivery systems e.g. nanoformulations<sup>(17-19)</sup>. In a recent study by Cheng et al. (2018) curcumin and cisplatin were co-encapsulated into the nanoliposomes<sup>(14)</sup>. The encapsulated curcumin and cisplatin as nanoparticles indicated the higher antineoplastic activity in comparison with free drug or encapsulated mono-drug therapy. In a recent *in vitro* study on SinaCurcumin®, synergistic antineoplastic effect of high dose nanocurcumin in combination with cisplatin has been reported<sup>(15)</sup>. Importantly, the authors declared that the effect was dose- and cell type-dependent. In the light of this pilot trial, further clinical study is needed to determine the suitable effective doses of nanocurcumin in the clinical setting. The lack of enough power and statistical significance to accept or reject the study hypothesis may expectedly be associated with the small sample size as the main limitation of the study. The authors acknowledge that the small sample size of the trial prevents any mean-

ingful inferences based on the study results. However, the present study describes the first clinical experience of nanocurcumin in bladder cancer patients undergoing chemotherapy and provides new insight into future clinical directions. Additional trials with a large number of patients will explain whether the nanocurcumin acts as a complementary therapy in these patients. Considering several experiences with different times of SinaCurcumin® supplementation<sup>(21-24)</sup>, we believe that a longer duration of supplementation seems to yield a better outcome. In a future well-designed trial, the pathologic response to chemotherapy could be used as a stronger surrogate endpoint. Since the majority of patients with the complete clinical response in the study received chemo-radiation instead of surgery procedure, the assessment of pathologic response as the primary endpoint was impossible in our study. In order to high rate of false positive results, CT scan and MRI are rarely used in the clinical setting after neoadjuvant chemotherapy<sup>(39)</sup>. Moreover, considering the role of distinct Genetic subtypes of bladder cancer in sensitivity of tumor to frontline Chemotherapy, the identification of different subtypes of bladder tumors may be helpful in future studies<sup>(40,41)</sup>. Finally, as the first report in the setting, this report summarized the possible mechanisms of action and some clinical directions for future investigations.

## CONCLUSIONS

These preliminary data suggest feasibility of nanocurcumin supplementation in this clinical setting and support further larger studies. This pilot study may also provide a substantial translational insight to fill the gap between the experiment and clinical practice. A large-scale randomized trial in the setting is warranted.

## CONFLICT OF INTEREST

The authors have declared that there is no conflict of interest.

## REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68:394-424.
2. Goel S, Sinha RJ, Bhaskar V, Aeron R, Sharma A, Singh V. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade. *Asian J Urol.* 2019;6:222-9.
3. Du B, Jiang L, Xia Q, Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. *Chemotherapy.* 2006;52:23-8.
4. Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. *J Neurochem.* 2007;102:522-38.
5. Montopoli M, Ragazzi E, Frolidi G, Caparrotta L. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. *Cell Prolif.* 2009;42:195-206.
6. Ke CS, Liu HS, Yen CH, et al. Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. *J Nutr Biochem.* 2014;25:526-39.
7. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. *Clin Cancer Res.* 2005;11:7490-8.
8. Zhang W, Shi H, Chen C, et al. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop. *Phytomedicine.* 2018;48:51-61.
9. Amanolahi F, Mohammadi A, Kazemi oskuee R, Golami L, Malaekheh-Nikouei B. Curcumin improved liposomal mitomycin-induced cell toxicity in bladder cancer cell. *Nanomed J.* 2018;5:235-44.
10. Afsharmoghadam N, Haghghatian Z, Mazdak H, Mirkheshti N, Mehrabi Koushki R, Alavi SA. Concentration- Dependent Effects of Curcumin on 5-Fluorouracil Efficacy in Bladder Cancer Cells. *Asian Pac J Cancer Prev.* 2017;18:3225-30.
11. Park BH, Lim JE, Jeon HG, et al. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2. *Oncotarget.* 2016;7:63870-86.
12. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. *Mol Cancer Ther.* 2007;6:1022-30.
13. Sreenivasan S, Krishnakumar S. Synergistic Effect of Curcumin in Combination with Anticancer Agents in Human Retinoblastoma Cancer Cell Lines. *Curr Eye Res.* 2015;40:1153-65.
14. Cheng Y, Zhao P, Wu S, et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. *Int J Pharm.* 2018;545:261-73.
15. Jafari A, Teymouri M, Ebrahimi Nik M, et al. Interactive anticancer effect of nanomicellar curcumin and galbanic acid combination therapy with some common chemotherapeutics in colon carcinoma cells. *Avicenna J Phytomed.* 2019;9:237-47.
16. Panda AK, Chakraborty D, Sarkar I, Khan T, Sa G. New insights into therapeutic activity and anticancer properties of curcumin. *J Exp Pharmacol.* 2017;9:31-45.
17. Liu W, Zhai Y, Heng X, et al. Oral bioavailability of curcumin: problems and advancements. *J Drug Target.* 2016;24:694-702.
18. Lagoa R, Silva J, Rodrigues JR, Bishayee A. Advances in phytochemical delivery systems

- for improved anticancer activity. *Biotechnol Adv.* 2019.
19. Gera M, Sharma N, Ghosh M, et al. Nanoformulations of curcumin: an emerging paradigm for improved remedial application. *Oncotarget.* 2017;8:66680-98.
  20. Yu K, Liu M, Dai H, Huang X. Targeted drug delivery systems for bladder cancer therapy. *J Drug Deliv Sci Tec.* 2020 101535.
  21. Ahmadi M, Agah E, Nafissi S, et al. Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. *Neurotherapeutics.* 2018;15:430-8.
  22. Alizadeh F, Javadi M, Karami AA, Gholaminejad F, Kavianpour M, Haghhighian HK. Curcumin nanomicelle improves semen parameters, oxidative stress, inflammatory biomarkers, and reproductive hormones in infertile men: A randomized clinical trial. *Phytother Res.* 2018;32:514-21.
  23. Dolati S, Aghebati-Maleki L, Ahmadi M, et al. Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial. *J Cell Physiol.* 2018;233:5222-30.
  24. Saadipoor A, Razzaghdoust A, Simforoosh N, et al. Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy. *Phytother Res.* 2019;33:370-8.
  25. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. *Pharm Stat.* 2005;4:287-91.
  26. Hatamipour M, Sahebkar A, Alavizadeh SH, Dorri M, Jaafari MR. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. *Iran J Basic Med Sci.* 2019;22:282-9.
  27. Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. *Onco Targets Ther.* 2014;7:1015-23.
  28. Pezzani R, Salehi B, Vitalini S, et al. Synergistic Effects of Plant Derivatives and Conventional Chemotherapeutic Agents: An Update on the Cancer Perspective. *Medicina (Kaunas).* 2019;55.
  29. Rayburn ER, Ezell SJ, Zhang R. Anti-Inflammatory Agents for Cancer Therapy. *Mol Cell Pharmacol.* 2009;1:29-43.
  30. Liu Z, Huang P, Law S, Tian H, Leung W, Xu C. Preventive Effect of Curcumin Against Chemotherapy-Induced Side-Effects. *Front Pharmacol.* 2018;9:1374.
  31. Fetoni AR, Eramo SL, Paciello F, et al. *Curcuma longa* (curcumin) decreases in vivo cisplatin-induced ototoxicity through heme oxygenase-1 induction. *Otol Neurotol.* 2014;35:e169-77.
  32. Kuhad A, Pilkhwai S, Sharma S, Tirkey N, Chopra K. Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. *J Agric Food Chem.* 2007;55:10150-5.
  33. Chen X, Wang J, Fu Z, et al. Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression. *Scientific Reports.* 2017;7:17724.
  34. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. *Adv Exp Med Biol.* 2007;595:105-25.
  35. Falke J, Parkkinen J, Vaahtera L, Hulsbergenvan de Kaa CA, Oosterwijk E, Witjes JA. Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model. *BioMed Res Int.* 2018;2018:7.
  36. Hauser PJ, Han Z, Sindhvani P, Hurst RE. Sensitivity of bladder cancer cells to curcumin and its derivatives depends on the extracellular matrix. *Anticancer Res.* 2007;27:737-40.
  37. Wang K, Tan SL, Lu Q, et al. Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer. *Am J Chin Med.* 2018;46:1357-68.
  38. Zhang W, Chen C, Shi H, et al. Curcumin is a biologically active copper chelator with antitumor activity. *Phytomedicine.* 2016;23:1-8.
  39. Patel SR, Hensel CP, He J, et al. Clinical Utility of Post-neoadjuvant Chemotherapy Computed Tomography for Muscle-Invasive Urothelial Bladder Cancer. *Urology Practice.* 2020 10.1097/UPJ.000000000000135.
  40. McConkey DJ, Choi W, Dinney CP. Genetic subtypes of invasive bladder cancer. *Curr Opin Urol.* 2015;25:449-58.
  41. Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. *Cancer Cell.* 2014;25:152-65.